Winding down, honoring commitments
PDL BioPharma, Inc. (pdl.com) earns a Brand Analyzer score of 71 out of 100, placing it in the Brand-Ready tier among Finance brands, Healthcare brands. Among 5211 Finance brands analyzed, PDL BioPharma, Inc. ranks in the 35th percentile (category average 75, leader 97). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 72/100, Digital Presence 67/100, Visual Identity 90/100, Messaging Clarity 95/100, Trust Foundation 93/100, AI Discoverability 72/100, Brand Authority 30/100.
PDL BioPharma, Inc. (pdl.com) is a formerly active biopharmaceutical company that is now in the process of formal dissolution under an approved Plan of Dissolution. Its investor relations website provides stockholders, investors, and creditors with updates on the wind-down of the company's business, including efforts to pay creditors and distribute remaining proceeds to stockholders. The company operates in the Finance and Healthcare categories, focused on transparent communication during liquidation rather than ongoing commercial operations.
| Brand Name | PDL BioPharma, Inc. |
|---|---|
| Domain | pdl.com |
| Industry | Finance, Healthcare |
| Founded | 2007 |
| Headquarters | Karl-Liebknecht-Haus |
| Main Competitors | Royalty Pharma (82/100), XOMA Corporation, Ligand Pharmaceuticals (82/100), Healthcare Royalty Partners (67/100) |
Moz Domain Authority 41/100 vs category average 38 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #2,522,921 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "The Investor Relations website contains information about PDL BioPharma, Inc." (Meta description: 10 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:type, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Drupal.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
PDL BioPharma, Inc. scores 31/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
PDL BioPharma, Inc. has a weak AI-visibility profile at 31/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is trust (43/100) and its weakest is visibility (17/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #2,522,921 (Tranco) and a Moz Domain Authority of 41/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify PDL BioPharma, Inc. from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is PDL BioPharma, Inc.?", Claude could identify the brand as of August 2026. PDL BioPharma was originally Protein Design Labs, a biotech company known for pioneering antibody humanization technology, and it later transformed into a royalty and asset management company that collected licensing income from patents used in blockbuster drugs like Herceptin, A Best known for Holding the Queen et al. antibody humanization patents and collecting royalties from major biotech drugs before winding down and dissolving as a company.
When asked "Best brands similar to PDL BioPharma, Inc.?", Claude would not surface PDL BioPharma, Inc. as of August 2026. It's a legacy biotech royalty company that dissolved and distributed its remaining assets to shareholders, so it's not really an active brand to recommend in today's finance space.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
PDL BioPharma, Inc.'s main competitors include Royalty Pharma (82/100), XOMA Corporation, Ligand Pharmaceuticals (82/100), Healthcare Royalty Partners (67/100). These companies compete in the Finance space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
PDL BioPharma, Inc. and Royalty Pharma are competitors in Finance. Brand Analyzer scores PDL BioPharma, Inc. at 71/100 and Royalty Pharma at 82/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to PDL BioPharma, Inc. include Royalty Pharma (82/100), XOMA Corporation, Ligand Pharmaceuticals (82/100), Healthcare Royalty Partners (67/100). Each is an established option in the Finance space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
PDL BioPharma, Inc. has limited AI-search visibility, scoring 31/100 on Brand Analyzer's AI visibility composite (visibility 17, trust 43, recommendation 43). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: PDL BioPharma, Inc. official site
PDL BioPharma, Inc. was founded in 2007. PDL BioPharma, Inc. operates in the Finance category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
PDL BioPharma, Inc. is headquartered in Karl-Liebknecht-Haus. PDL BioPharma, Inc. operates in the Finance category.
Sources: Wikidata
PDL BioPharma, Inc. scores 43/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Finance options. Recommendation depends on crawlability, structured data, and category authority.
Sources: PDL BioPharma, Inc. official site
PDL BioPharma, Inc. can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: PDL BioPharma, Inc. official site
PDL BioPharma, Inc. is a formerly operating biopharmaceutical company that is now undergoing a formal corporate dissolution. Its current activity centers on winding up its business affairs under an approved Plan of Dissolution, which includes paying off creditors and distributing any remaining assets to stockholders. The company's website, pdl.com, functions primarily as an investor relations portal providing updates on this liquidation process.
Sources: PDL BioPharma, Inc. official site
The company's information is used by current and former stockholders, investors, and creditors of PDL BioPharma who seek updates on the company's dissolution and liquidation process, including details on asset distribution and creditor settlements.
Sources: PDL BioPharma, Inc. official site
Ranked closest to PDL BioPharma, Inc.: Spire (71/100), Payman AI (71/100), Peach (71/100), PHP Agency (71/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zoya (81/100).
Category leader: Les Echos (97/100).